Phase 2 RCT: Anti-tumor necrosis factor therapy for early-stage Dupuytren’s disease.

Anti-tumour necrosis factor therapy for early-stage Dupuytren’s disease (RIDD): a phase 2b, randomised, double-blind, placebo-controlled trial – The Lancet Rheumatology

News Release: Breakthrough in treatment for Dupuytren’s disease – University of Oxford

Commentary: Treatment for finger-bending disease may be ‘gamechanger’ – The Guardian

Commentary on Twitter

NEW RESEARCH—Intranodular injections of anti-tumour necrosis factor therapy (adalimumab) for early-stage Dupuytren's disease: a phase 2b, randomised, double-blind, placebo-controlled trial https://t.co/Jz9QUJEzS8 #LancetRheumatology #OpenAccess pic.twitter.com/mcZj9GK4l4

— The Lancet Rheumatology (@TheLancetRheum) May 4, 2022